Introduction
Psoriatic arthritis (PsA) is a painful, often disabling inflammatory arthritis associated with psoriasis. 1 Psoriasis affects approximately 2% of the Caucasian population, and arthritis occurs in about 11% of both male and female patients with psoriasis. 2 Despite considerable heterogeneity in the presentation of arthropathy and the extent of skin disease, genetic studies support the notion that PsA is a distinct disease entity with a strong heritable component. 3 While a number of genetic loci have been associated with psoriasis and PsA, 4 the number of genes linked to both psoriasis and PsA is limited. 5 Few serologic or proteomic biomarkers exist to aid in diagnosis or monitoring of disease activity.
Histopathologic changes in psoriatic plaques include activation and expansion of keratinocytes, and accumulation of T cells, B cells, macrophages and neutrophils. 1 Activation of both CD4 and CD8T cells has been implicated in the pathogenesis of the skin and joint phenotype. One of the major inflammatory molecules implicated in PsA pathogenesis is the cytokine tumor necrosis factor-alpha (TNF-a). 1 Although recent clinical trials of TNF-a inhibitors in PsA have shown effectiveness in controlling skin manifestations and in alleviating musculoskeletal symptoms, 6 a significant number of PsA patients fail to respond to TNF inhibition. Given the expense and potential toxicity of anti-TNF agents, clinical predictors of response to treatment are urgently needed.
Recently, studies utilizing microarray technology to survey gene expression profiles have generated new hypotheses concerning the pathogenesis of complex autoimmune disorders. 7 Analyses of differential gene expression in peripheral blood cells of patients with disorders such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have identified several gene 'signatures', groups of genes that are differentially expressed in patients as compared to controls. [8] [9] [10] In some cases, differentially expressed genes correlate with particular disease manifestations, with disease activity scores, or with responsiveness to treatment regimens. These observations serve as 'proof of principle' that for systemic inflammatory diseases in general, peripheral blood gene expression profiling can be applied to disease diagnosis and monitoring, and to the identification of novel therapeutic targets.
The goal of this study was to examine the utility of gene expression profiling as a hypothesis generating and diagnostic tool in PsA. The results suggest that PsA patients exhibit a peripheral blood gene expression profile distinct from both healthy controls and from that observed in other systemic autoimmune states (e.g. the 'interferon signature' observed in SLE 8, 10, 11 or the 'monocyte signature' of RA 9 ). Additionally, logistic regression analysis identified two lymphocyte-specific genes that most accurately discriminate patients from controls in this discovery sample. Highly coregulated genes that correlate most closely with inflammation include two members of the RAS oncogene family (RAB13 and RAB32) which are implicated in the inhibition of protein kinase A (PKA) activity. A number of differentially expressed genes observed in PsA blood are commensurate with previous observations of disease dependency upon T-cell function, but also suggest possible roles for genes involved in apoptosis, cell adhesion, chemokine/cytokine signaling, G-protein coupled signaling and B-cell-mediated immunity. Further, both the costimulatory molecule CD40 and its ligand are among a number of adaptive immune cell genes downregulated in PsA patients compared to controls.
Results
Whole blood gene expression profiles of PsA patients are distinct from profiles of age-and sex-matched controls We analyzed gene expression profiles in whole blood obtained from 16 PsA patients and 15 normal controls. Patient demographic and clinical data are summarized in Table 1 . The following criteria were applied to generate a list of genes that were differentially expressed between PsA patients and normal controls: (a) P-value o0.00001 by an unpaired Student's t-test for the difference in mean expression level between groups; (b) greater than a twofold change in the mean expression level between the two groups. Initially, we obtained a list of 578 differentially regulated transcripts. After filtering multiple probe sets for any one gene, our focus was narrowed by removing genes that had an absolute difference between patient and control mean intensity values of less than 500, and by excluding genes encoding hypothetical proteins and non-descript mRNAs. Of approximately 12 070 genes expressed in whole blood, we identified a group of 310 genes that were differentially expressed in PsA patients ( Figure 1 ). As we expected, all of the patients clustered together by unsupervised hierarchical clustering, while the controls clustered independently. Among the 310 differentially expressed genes, 236 were upregulated in patients vs controls, while 74 were downregulated. These results suggest that peripheral blood gene expression profiles can distinguish PsA from normal controls. The PsA gene expression profile shows little overlap with gene expression profiles of other inflammatory autoimmune diseases or with cytokine-driven gene profiles PsA shares a number of clinical features with other systemic inflammatory syndromes and arthropathies such as RA and SLE. To learn whether these conditions exhibit overlapping gene expression profiles, the PsA gene list was compared to differentially expressed gene lists generated from recent expression profiling studies in RA 9 and SLE. 8 Direct comparison of raw gene chip data between these groups was not possible due to different methods of RNA preparation and utilization of earlier generations of Affymetrix chips for the RA and SLE investigations. In order to compare the gene lists; we determined a common denominator to which all disease lists were compared. This denominator included 5877 genes that were present on all chips used for analysis, and were expressed in whole blood. Using w 2 analysis, significance of overlap was determined between the filtered disease lists. Despite clinical observations that both PsA and RA are systemic inflammatory disorders manifesting similar pannus-producing arthropathies, only three genes were found to be coordinately and differentially expressed in both disorders (RAB13, RAB32, Fc fragment of IgG binding protein). This overlap is not greater than what would be expected by chance alone.
One of the overlapping genes, RAB32, belongs to the monocyte 'signature' recently described for RA. 9 When the PsA list was compared to a list of genes reported to be differentially regulated in SLE, no significant overlap was observed. The single overlapping gene did not belong to either the interferon 8, 10 or the granulocyte 'signatures' recently associated with clinical SLE 10 (not shown). While technical differences between the current study and the RA or SLE profiling experiments limit interpretation, these comparisons do not suggest similarity between blood cell gene expression patterns observed in these autoinflammatory syndromes and PsA.
TNFa and IL-1b are apical molecules in cytokine cascades that play roles in a number of autoimmune inflammatory conditions, including PsA. 4 We hypothesized that differentially expressed genes in peripheral blood of PsA patients would be regulated by these cytokines. In order to identify gene expression patterns characteristic of cytokine stimuli, profiles were determined for normal PBMCs incubated with either medium alone or with saturating concentrations of IL-1b or TNF (EC Baechler and TW Behrens, unpublished results). Comparison of differentially expressed genes induced by IL-1b or TNF revealed that these stimuli regulate highly overlapping sets of genes, consistent with work indicating significant cross-talk between these proinflammatory cytokines (data not shown). 12 When the cytokinestimulated gene lists were compared to the PsA patient gene list, no greater overlap was observed with either cytokine than what was expected by chance alone. The paucity of overlapping genes between PsA and cytokine-stimulated PBMCs may suggest that the reported heightened activity of TNFa and IL-1b in PsA patients 13 is not clearly reflected in whole blood gene expression profiles.
Individual genes have high discriminatory potential for disease diagnosis Currently, specific and sensitive blood-derived diagnostic tests for PsA are not available. We employed logistic regression analysis to explore the potential utility of individual differentially expressed genes in the discrimination of PsA patients from normal controls. Figure 2 shows individual expression levels for the four genes identified by this analysis to have the highest discriminatory potential: zinc-finger protein 395 (ZNF395), dead box polypeptide 28, pecanex-like 3, and phosphoinositide-3-kinase, class 2, beta polypeptide (PI3KC2B). Dead box polypeptide 28 and pecanex-like 3 are expressed ubiquitously, while expression of ZNF395 and PI3KC2B is observed specifically in lymphocytes (Novartis atlas, http://symatlas.gnf.org/SymAtlas/). ZNF395 has been implicated in regulation of neuronal cell genes, and PI3KC2B has been implicated in epidermal differentiation, but no functions for these genes have been described in hematopoietic cells. 14, 15 These results suggest that detection of whole-blood expression levels of a small group of genes may be useful for confirming a PsA clinical diagnosis.
Coregulated gene clusters are enriched for genes that are implicated in adaptive immune cell function and for genes with expression levels that correlate with erythrocyte sedimentation rate To determine whether groups of coregulated, differentially expressed genes in PsA correlate with clinical parameters, correlation coefficients (r-values) were calculated for clinical criteria vs gene expression values. We observed enrichment of upregulated genes exhibiting positive correlation with erythrocyte sedimentation rate (ESR) within a highly coregulated group of genes ( Figure 1 , vertical bar A). Specific genes in this group are listed in Figure 3a ; genes exhibiting significant correlation coefficients (Po0.05, corresponding to r40.6) with patient ESR values are highlighted in blue. To determine the significance of the correlations between gene expression and clinical features, P-values were generated by random permutation of the dataset. Among the coregulated genes are several RAB family members (small molecular weight G-proteins), two of which -RAB13 and RAB32 -have been implicated in protein kinase A (PKA) cellular localization and inhibition of PKA signaling. 16, 17 Although significant correlations were found between individual genes and other clinical parameters, none of these genes fit into highly coregulated groups. These results suggest that RAB family members implicated in PKA signaling are coregulated and correlate with a measure of systemic inflammation in PsA whole blood. The list shown in Figure 3b contains individual downregulated genes that are tightly coregulated (Figure 1 , vertical bar B). Many of these genes are involved in T-or B-cell development or function, including CD74, Fyn, RUNX3 and the IL-2 receptor 'common' gamma chain. Thus, a number of genes implicated in lymphocyte functions are coregulated and suppressed in PsA blood. Suppression of these genes is not likely indicative of significant reduction in PsA lymphocyte numbers, since none of the patients display lymphopenia (Table 1; normal range for lymphocyte count is 0.9-2.9 Â 10 3 /ml), and since other lymphocyte-specific genes are upregulated in patients vs controls (Figure 4 ).
Differentially expressed genes in PsA can be classified into several functional categories
To highlight potential functional pathways represented among the differentially expressed genes in PsA patients, we utilized public, annotated databases to group them into broad functional categories. Organization of genes based on participation in cellular processes according to the Panther Classification System (Applied Biosystems) led to the observation that multiple differentially expressed genes in PsA are implicated in functions including apoptosis, cell adhesion, cytokine/ chemokine signaling, G-protein signaling and adaptive immunity. Figure 4 illustrates subsets of genes that were classified into the above-mentioned pathways and indicates the mean fold change in gene expression between PsA patients and healthy controls.
Further pathway analysis was conducted using the Ingenuity Pathway Analysis Network Generation Algorithm (www.ingenuity.com). This system groups a selection of genes into networks based on Ingenuity's Pathways Knowledge Base (IPKB). The IPKB constructs putative functional networks based on primary literature evidence for protein-protein interactions. Of the 310 differentially expressed genes, 146 genes could be assigned to networks based on IPKB classification. A network centered on CD40 signaling contained a substantial number (20) of differentially expressed PsA genes. Within this network, CD40, its ligand (CD40LG), and seven other genes were downregulated in PsA patients (Table 2) . Thus, over 10% of the total number of downregulated genes in PsA are present in the CD40centered network. Using real-time RT-PCR, we verified the microarray-based observations of downregulation of a number of genes in this pathway, including CD40, CD40LG and CD74 (data not shown). Although CD40 is expressed predominantly on B cells and a decrease in B cell peripheral blood numbers has recently been linked to methotrexate treatment in SLE patients, 18 we found no significant differences in mean CD40 or CD40LG expression levels when comparing patients treated with methotrexate or with other DMARDs and untreated patients (data not shown). Therefore, it is unlikely that DMARD treatment contributes to the observed downregulation of CD40 expression in PsA patients. In summary, the pathway analysis demonstrates that differentially expressed genes in PsA fall into a number of functional categories, and that many genes encoding members of a network of proteins implicated in CD40 signaling are downregulated in PsA patient blood.
Discussion
Compared to healthy controls, PsA patients display whole blood gene-expression profiles characterized by a predominance of upregulated genes. This profile does not significantly overlap with profiles derived from other inflammatory autoimmune diseases, although a few PsA genes are regulated in common with genes differentially Gene-expression profiling in psoriatic arthritis AK Stoeckman et al expressed in RA and SLE patient PBMCs or in cytokinetreated PBMCs. In keeping with existing hypotheses concerning the pathogenesis of PsA, the differentially expressed genes encode molecules implicated in T-cell signaling. A highly coregulated subset is enriched for genes that positively correlate with ESR, and thus reflect inflammation. A small panel of lymphocytespecific genes with potential to discriminate PsA patients from controls was identified. Finally, differentially expressed genes in PsA blood fall into diverse functional networks, but a high proportion of downregulated genes can be classified as part of a CD40-centered pathway.
Previous studies of peripheral blood in PsA or psoriasis patients utilizing gene expression profiling are limited. Koczan et al. 19 recently reported on microarray experiments conducted on isolated PBMCs from 11 psoriasis patients. Eighteen differentially expressed genes (all upregulated) in the 'disease' stage compared to the 'cured' (post-treatment) stage were reported. None of the PsA differentially expressed genes in the current study were among the genes reported by Koczan, possibly due to ex vivo PBMC purification procedures used by the latter or to the lack of comparison against normal controls. In a smaller microarray-based study by Gu et al., 20 14 genes were found to be upregulated in the peripheral blood cells of a majority of six PsA patients compared to controls. Although a number of the overexpressed genes found in PsA patients fit into relevant inflammation pathways (e.g. proinflammatory cytokines and receptors, signaling molecules), only one gene reported in that study (IL-2 receptor gamma) was also found to be differentially expressed in the current study. Such differences from the current study may be explained by the usage of a restricted 588-gene chip, inclusion of only six patients with PsA, and subjection of blood samples to PBMC isolation procedures before gene expression profiling.
Reagents and methods used in the current study represent several departures from previous studies. First, the HG-U133Plus 2.0 chip contains a greatly expanded collection of transcripts compared to the HGU95A chip used in the Koczan study or the Atlas Human Array filter 7740-1 used by Gu et al. Second, in the current study, PAXgene collection tubes containing RNA stabilizing reagents were used for preparation of total RNA from whole blood of patients. Baechler et al. 21 have shown that the regulation of hundreds of peripheral blood genes is sensitive to ex vivo handling, transport and PBMC purification procedures. Our use of PAXgene tubes avoided potential artifacts introduced by the in vitro manipulation of blood cells. Use of later-generation hybridization platforms and whole blood RNA sources, however, limits the ability to compare profiles with those from earlier studies. As recently published profiling studies in RA and SLE used purified PBMCs as an RNA source and generated hybridization data on earlier generations of chips, 8, 9 it is a challenge to compare results with those of the current PsA study. Nevertheless, these studies employed filtering procedures to generate differentially expressed gene lists similar to those utilized in the current study, and it is notable that list comparison does not suggest significant overlap among differentially expressed genes in these conditions and in PsA.
As both TNF and IL-1 are strongly upregulated in PsA synovial fluid, 22 and TNF inhibitors have recently shown dramatic efficacy in a subset of patients with PsA, 6 the observed lack of overlap between expression profiles from PsA blood and from TNF or IL-1 treated PBMCs is surprising. It is possible that in PsA patients, altered transcription engendered by these cytokines may be occurring primarily in microenvironments of affected tissues (e.g. patient joints and skin) rather than in circulating blood cells. Certainly, elevated immunoreactivity and biological activity of TNFa in the lesions of psoriasis patients have been described. 23 However, as with the RA and SLE differentially expressed gene lists, technical differences between the generation of the PsA and of the cytokine-treated PBMC gene lists suggest that comparative analysis of expression profiles should be interpreted cautiously.
In addition to a comparison analysis between the PsA differentially expressed gene list and gene lists from other diseases or cytokine treatment, we performed logistic regression analysis in order to identify genes with the best discriminatory potential between PsA patients and controls. All four genes (ZNF395, pecanexlike 3, PI3KC2B, and dead box polypeptide 28) with the strongest ability to discriminate patients from controls were downregulated in the PsA patients. Pecanex-like 3 and dead box polypeptide 28 exhibit ubiquitous expression, while both ZNF395 and PI3KC2B show highest expression levels in peripheral blood CD19 þ B cells (Novartis atlas, http://symatlas.gnf.org/SymAtlas/). Determination of expression levels for small panels of genes like the four listed above may have application in confirming diagnosis of or in monitoring disease activity in PsA. However, validation of these genes as tools for clinical application will require longitudinal studies in larger, well-characterized PsA patient populations. Such studies should also be adequately powered to address important clinical issues like prediction of response to treatment with biological response modifiers.
T cells have long been recognized as key players in the pathogenesis of PsA. 24 We identified a number of genes involved in T-cell immunity which were included in a highly coregulated gene cluster: CD3e, IL-2 receptor ('common') gamma chain, RUNX3 and Fyn. CD3e is a transmembrane adaptor protein that couples T-cell receptor ligand recognition with activation of protein tyrosine kinases. 25 Fyn is a membrane-associated protein tyrosine kinase required for optimal Th2 cytokine production, suppression of Th1-mediated autoimmune disease, and maintenance of T-cell anergy. [26] [27] [28] Loss of RUNX3 transcription factor activity in mice is associated with autoimmune disease [29] [30] [31] as well as the skewing of CD4/CD8 T-cell development. 32 The observed downregulation of these T-cell-expressed genes in PsA blood agrees with both the negative regulatory functions assigned to many of these genes and with the model of PsA as a T-cell-dependent inflammatory disease.
A subset of highly coregulated genes is enriched for upregulated genes whose expression levels significantly correlate with ESR, a non-specific measure of the systemic inflammatory response. Two of these genes are RAB family members shown to be involved in negative regulation of PKA activity. 16, 17 As signaling through PKA downregulates T-cell responses to antigen, 33 the inhibition of PKA by RAB13 and RAB32 could lead to enhanced T-cell activity. This is consistent with the hyperactivity of T cells observed in inflammatory autoimmune diseases such as PsA.
B cells may also play a role in the pathogenesis of PsA. 24 Ingenuity pathway analysis of the differentially expressed PsA genes revealed the suppression of numerous genes within a network centered on CD40, a TNF receptor superfamily member required for B-cell function. 34 Although increased signaling through CD40 has previously been shown to be important in the development of psoriasis, RA and SLE [35] [36] [37] we observed the downregulation of CD40, CD40 ligand and a number of CD40 signaling intermediates in whole blood of PsA patients. Decreased numbers of B cells in the circulating blood of PsA patients does not likely account for decreased CD40 expression, since other B-cell specific genes (e.g. Ig heavy chain) are upregulated in PsA patients. Additionally, evidence in the literature indicates no decrease in the absolute number of B cells in the peripheral blood of PsA patients vs healthy controls. 38, 39 Selective recruitment of B cells or other CD40-expressing leukocytes (e.g. CD11c þ dendritic cells) out of the blood and into sites of pathology is an alternative explanation, given observations of enhanced CD40 expression in psoriatic lesions. 40, 41 
Patients and methods

Study participants
This study was approved by the Institutional Review Boards at the Mayo Clinic and the University of Minnesota. All patients were recruited through the Rheumatology clinic at the Mayo Clinic (Rochester, MN, USA), and all patients met the American College of Rheumatology criteria for diagnosis. Informed written consent was obtained from patients who provided blood samples. The study included 16 Caucasian patients with PsA. At the time of sample collection, 94% had active psoriasis and 75% had active joint disease. Clinical data, including swollen joint counts, disease activity score and laboratory results (erythrocyte sedimentation rate, C reactive protein levels and peripheral blood cell counts), were obtained at the time of sample acquisition. A single observer (CJM) performed all clinical assessments and chart review. Healthy (self-reported) controls were matched for age (within 3 years of patient ages) and race. The controls included three males and 12 females.
RNA isolation and labeling
Venous blood (10 ml) was collected in PAXgene sample tubes (PreAnalytiX). Total RNA was obtained using the PAXgene Blood RNA Kit per manufacturer's instructions. RNA was quantified using the Agilent RNA 6000 Nano Assay Protocol. Typical yield of total RNA was 40 mg per 10 ml of blood. Subsequent cDNA/ cRNA synthesis was performed with 1 mg of total RNA using the MessageAmp aRNA Kit (Ambion). The cRNA was labeled with Biotin-11-CTP (Perkin Elmer) and Biotin-16-UTP (Roche) before hybridization.
Microarray analysis and quality control
Labeled cRNA (15 mg) was fragmented and hybridized to Affymetrix HG-U133 Plus 2.0 chips in the Biomedical Image Processing Laboratory at the University of Minnesota. The Affymetrix HG-U133 Plus 2.0 chip contains greater than 54 000 probe sets representing approximately 38 500 genes. Genedata Expressionist Refiner was used to assess the quality of chip hybridization. Each chip was scaled to an average intensity of 1500 to adjust for global differences in hybridization. Factors used to determine successful chip hybridization included levels of background and noise, percent of probes considered positive, and 3 0 -5 0 ratios of control genes (actin and GAPDH).
Data acquisition and cluster analysis
Genedata Expressionist (5.0.6) was used to obtain gene expression values (intensities) for each gene. The following criteria were applied to generate a list of genes that were differentially expressed between PsA patients and normal controls: (A) P-value of o0.00001 by an unpaired Student's t-test; (B) greater than a twofold change in the mean gene expression between the two groups. The list was further filtered by removing genes that had an absolute difference between patient and control mean intensity values that was less than 500, and by excluding hypothetical proteins and non-descript mRNAs. The expression values of the differentially expressed genes were log 2 transformed and then used to perform unsupervised hierarchical clustering with the use of the program CLUSTER. Clustering results were viewed with the TREEVIEW software. 42 To determine the number of genes expressed in whole blood, intensity values for the 54 675 probe sets were examined, and genes with average values below 600 for either patients or controls were removed. Multiple probe sets for a single gene, hypothetical proteins, and non-descript mRNAs were then eliminated.
Comparison analysis
In order to appropriately compare differentially expressed gene lists between diseases, a common gene list was determined. Of the 12 070 HG-U133 Plus 2.0 genes expressed in whole blood, the corresponding probe sets not also represented on the previous generations of chips (those used in RA, SLE and cytokine studies) were eliminated. In addition, we removed genes affected by ex vivo handling and PBMC purification procedures. 21 All differentially expressed disease gene lists were filtered according to this common list. Significance for gene overlap was determined by chi square analysis.
Logistic regression analysis
Logistic regression analysis to determine genes with high discriminative potential for affected status was carried out using the glm function in R's statistical package and specifying a binomial model with a logit link.
